Molecular targets for endogenous glial cell line-derived neurotrophic factor modulation in striatal parvalbumin interneurons.

ABSTRACT: Administration of recombinant glial cell line-derived neurotrophic factor into the putamen has been tested in preclinical and clinical studies to evaluate its neuroprotective effects on the progressive dopaminergic neuronal degeneration that characterizes Parkinson's disease. However, intracerebral glial cell line-derived neurotrophic factor infusion is a challenging therapeutic strategy, with numerous potential technical and medical limitations. Most of these limitations could be avoided if the production of endogenous glial cell line-derived neurotrophic factor could be increased. Glial cell line-derived neurotrophic factor is naturally produced in the striatum from where it exerts a trophic action on the nigrostriatal dopaminergic pathway. Most of striatal glial cell line-derived neurot

SUBMITTER: Enterria-Morales D 

PROVIDER: S-EPMC7472905 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature